Pretreatment patient characteristics
| Variable . | Total cohort, N = 664 . | Younger patients (<60 y), N = 376 . | Older patients (≥60 y), N = 288 . |
|---|---|---|---|
| Age (y) | |||
| Median | 57 | 45 | 67 |
| Range | 18-86 | 18-59 | 60-68 |
| Female gender, n (%) | 330 (50) | 203 (54) | 127 (44) |
| De novo AML | 570 (86) | 335 (89) | 235 (82) |
| Secondary AML | 59 (9) | 22 (6) | 37 (13) |
| Therapy-related AML | 35 (5) | 19 (5) | 16 (6) |
| ECOG performance status, n (%) | |||
| 0 | 172 (27) | 111 (30) | 61 (22) |
| 1 | 313 (48) | 175 (47) | 138 (49) |
| 2 | 125 (19) | 59 (16) | 66 (24) |
| 3 | 33 (5) | 20 (5) | 13 (5) |
| 4 | 6 (1) | 4 (1) | 2 (1) |
| WBC count, ×109/L | |||
| Median | 23.4 | 25.7 | 20.9 |
| Range | 0.1-666 | 0.1-486 | 0.5-666 |
| Hemoglobin, g/dL | |||
| Median | 9.0 | 9.0 | 9.0 |
| Range | 3.5-16.0 | 3.5-15.6 | 3.8-16 |
| Platelet count, ×109/L | |||
| Median | 53 | 52 | 55 |
| Range | 1-1760 | 1-1760 | 1-471 |
| Bone marrow blasts, % | |||
| Median | 80 | 80 | 80 |
| Range | 6-100 | 6-100 | 9-100 |
| FAB category, n | |||
| M0 | 35 | 16 | 19 |
| M1 | 157 | 80 | 77 |
| M2 | 178 | 93 | 85 |
| M4 | 163 | 107 | 56 |
| M5 | 83 | 51 | 32 |
| M6 | 19 | 11 | 8 |
| M7 | 3 | 3 | 0 |
| MRC cytogenetic risk category | |||
| Favorable | 65 (10) | 50 (14) | 15 (5) |
| Intermediate | 452 (70) | 254 (69) | 198 (71) |
| Adverse | 129 (20) | 65 (18) | 64 (23) |
| Modified ELN classification* | |||
| Favorable | 189 (29) | 128 (35) | 61 (22) |
| Intermediate-I | 205 (32) | 107 (29) | 98 (35) |
| Intermediate-II | 119 (18) | 62 (17) | 57 (21) |
| Adverse | 133 (21) | 72 (20) | 61 (22) |
| NPM1-mutated, n (%) | 221 (33) | 129 (34) | 92 (32) |
| FLT3-ITD present, n (%) | 197 (30) | 119 (32) | 78 (27) |
| CEBPA, n (%) | |||
| Single mutation | 25 (4) | 13 (3) | 12 (4) |
| Double mutation | 27 (4) | 22 (6) | 5 (2) |
| DNMT3A-mutated, n (%) | 209 (31) | 108 (29) | 101 (35) |
| RUNX1-mutated, no. (%) | 102 (15) | 35 (9) | 67 (23) |
| TP53 mutated, n (%) | 63 (9) | 23 (6) | 40 (14) |
| Variable . | Total cohort, N = 664 . | Younger patients (<60 y), N = 376 . | Older patients (≥60 y), N = 288 . |
|---|---|---|---|
| Age (y) | |||
| Median | 57 | 45 | 67 |
| Range | 18-86 | 18-59 | 60-68 |
| Female gender, n (%) | 330 (50) | 203 (54) | 127 (44) |
| De novo AML | 570 (86) | 335 (89) | 235 (82) |
| Secondary AML | 59 (9) | 22 (6) | 37 (13) |
| Therapy-related AML | 35 (5) | 19 (5) | 16 (6) |
| ECOG performance status, n (%) | |||
| 0 | 172 (27) | 111 (30) | 61 (22) |
| 1 | 313 (48) | 175 (47) | 138 (49) |
| 2 | 125 (19) | 59 (16) | 66 (24) |
| 3 | 33 (5) | 20 (5) | 13 (5) |
| 4 | 6 (1) | 4 (1) | 2 (1) |
| WBC count, ×109/L | |||
| Median | 23.4 | 25.7 | 20.9 |
| Range | 0.1-666 | 0.1-486 | 0.5-666 |
| Hemoglobin, g/dL | |||
| Median | 9.0 | 9.0 | 9.0 |
| Range | 3.5-16.0 | 3.5-15.6 | 3.8-16 |
| Platelet count, ×109/L | |||
| Median | 53 | 52 | 55 |
| Range | 1-1760 | 1-1760 | 1-471 |
| Bone marrow blasts, % | |||
| Median | 80 | 80 | 80 |
| Range | 6-100 | 6-100 | 9-100 |
| FAB category, n | |||
| M0 | 35 | 16 | 19 |
| M1 | 157 | 80 | 77 |
| M2 | 178 | 93 | 85 |
| M4 | 163 | 107 | 56 |
| M5 | 83 | 51 | 32 |
| M6 | 19 | 11 | 8 |
| M7 | 3 | 3 | 0 |
| MRC cytogenetic risk category | |||
| Favorable | 65 (10) | 50 (14) | 15 (5) |
| Intermediate | 452 (70) | 254 (69) | 198 (71) |
| Adverse | 129 (20) | 65 (18) | 64 (23) |
| Modified ELN classification* | |||
| Favorable | 189 (29) | 128 (35) | 61 (22) |
| Intermediate-I | 205 (32) | 107 (29) | 98 (35) |
| Intermediate-II | 119 (18) | 62 (17) | 57 (21) |
| Adverse | 133 (21) | 72 (20) | 61 (22) |
| NPM1-mutated, n (%) | 221 (33) | 129 (34) | 92 (32) |
| FLT3-ITD present, n (%) | 197 (30) | 119 (32) | 78 (27) |
| CEBPA, n (%) | |||
| Single mutation | 25 (4) | 13 (3) | 12 (4) |
| Double mutation | 27 (4) | 22 (6) | 5 (2) |
| DNMT3A-mutated, n (%) | 209 (31) | 108 (29) | 101 (35) |
| RUNX1-mutated, no. (%) | 102 (15) | 35 (9) | 67 (23) |
| TP53 mutated, n (%) | 63 (9) | 23 (6) | 40 (14) |
ECOG, Eastern Cooperative Oncology Group; ELN, European LeukemiaNet; FAB, French-American-British classification; ITD, internal tandem duplication; MRC, British Medical Research Council.
Modified ELN classification designates the ELN reporting system for genetic alterations14; however only patients with double, and not those with single, CEBPA mutations were classified as “favorable.”